Jetzt bei 3 Monate Wertpapiere um EUR 1,- handeln und EUR 50,- Startbonus sichern!-w-
30.10.2020 11:05:00

Why Vertex Hit a Home Run With Its Q3 Results, but Few Are Cheering

Vertex Pharmaceuticals' (NASDAQ: VRTX) great year screeched to a halt a couple of weeks ago. The company pulled the plug on a phase 2 study evaluating alpha-1 antitrypsin deficiency (AATD) candidate VX-814 because of safety concerns. All of the big gains Vertex had generated so far in 2020 evaporated.Investors hoped for some good news from Vertex with its third-quarter update after the market closed on Thursday. The reality is that Vertex pretty much hit a home run in Q3 for shareholders, and even more so for cystic fibrosis (CF) patients. However, it's likely that few investors are cheering those results. Image source: Getty Images.Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"